Malaysia's genomic diversity ideal for clinical trial site - KJ

The genomic diversity of Malaysia, due to its diverse population, offers the ideal site for clinical trial research, said Health Minister Khairy Jamaluddin.

He said genetic differences are one of the important aspects researchers look for in clinical trials, especially in testing the efficacy of treatment.

He said this is why Malaysia is the best destination as there is no other country in the world which has one-third of the world's genomic profile.

“One-third of the world is either Chinese and Indian and we have that here in Malaysia. We also have huge other chunks including the Malay genomics profile.

“In science, genetic differences do make a difference as far as efficacy of treatment is concerned,” he said.

He was speaking at a signing ceremony between Novartis Malaysia, Clinical Research Malaysia and the Sarawak General Hospital in Kuching, today.

Meanwhile, Khairy (above) said Malaysia also offers one of the lowest costs for clinical research and clinical trials in the region.

“Our time of trial is also one of the fastest in the world, from submission to ethical review in just one month.

“This has resulted in Malaysia now being the number two country in South East Asia for the number of industry-sponsored clinical trials right now,” he said.

Khairy said since 2012, Malaysia has conducted over 1,900 sponsored clinical research projects.

“Last year, Malaysia conducted 215 new sponsored clinical research projects for a total contract value of RM226 million,” he added.

- Bernama

M’sia keen to learn from Thailand on use of medical cannabis products

KJ on fact-finding visit to Thailand on potential medical use of cannabis

Sars-related coronaviruses infect 66k SE Asians a year - study

M'sia to lead development of clinical trials of drugs to treat dengue